Literature DB >> 20459885

Antidepressant-like action of intracerebral 6-fluoronorepinephrine, a selective full α-adrenoceptor agonist.

Eric A Stone1, Yan Lin, Yasmeen Sarfraz, David Quartermain.   

Abstract

The present study examined the ability of 6-fluoronorepinephrine (6FNE), a full selective α-adrenoceptor agonist, to produce antidepressant-like effects in mice. The drug, administered in the 4th ventricle, produced marked anti-immobility effects at mid-dose range in the acute forced swim, tail suspension and repeated open-space forced swim tests with minimal effect on open-field motor activity and also reversed anhedonia following lipopolysaccharide administration. Its antidepressant effects were equal to or greater than that of an established systemic antidepressant, desmethylimipramine, given subacutely. Experiments with α-adrenoceptor antagonists indicated that the drug acts primarily via the α2-receptor in contrast to endogenous catecholamines which appear to control depressive behaviour primarily via the α1-receptor. Antidepressant activity declined at higher doses signifying a possible pro-depressant effect of one of the α-adrenoceptor subtypes. Compared to the selective α2-agonist, dexmedetomidine, 6FNE showed equivalent antidepressant action in the tail suspension test but appeared to have a greater efficacy or speed of action in the repeated open-space forced swim test which produces a more sustained depression. Studies of regional brain Fos expression induced during the antidepressant tests showed that 6FNE tended to inhibit neural activity in two stress-responsive regions (locus coeruleus and paraventricular hypothalamus) but to enhance activity in two areas involved in motivated behaviour (nucleus accumbens shell and lateral septal nucleus) producing a neural pattern consistent with antidepressant action. It is concluded that 6FNE elicits a rapid and effective antidepressant and anti-stress response that may compare favourably with available antidepressants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20459885     DOI: 10.1017/S1461145710000507

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  7 in total

1.  A Basal Forebrain Site Coordinates the Modulation of Endocrine and Behavioral Stress Responses via Divergent Neural Pathways.

Authors:  Shane B Johnson; Eric B Emmons; Rachel M Anderson; Ryan M Glanz; Sara A Romig-Martin; Nandakumar S Narayanan; Ryan T LaLumiere; Jason J Radley
Journal:  J Neurosci       Date:  2016-08-17       Impact factor: 6.167

2.  Participation of brainstem monoaminergic nuclei in behavioral depression.

Authors:  Yan Lin; Yasmeen Sarfraz; Ashley Jensen; Adrian J Dunn; Eric A Stone
Journal:  Pharmacol Biochem Behav       Date:  2011-08-26       Impact factor: 3.533

Review 3.  α2 adrenergic receptor dysregulation in depressive disorders: implications for the neurobiology of depression and antidepressant therapy.

Authors:  Christopher Cottingham; Qin Wang
Journal:  Neurosci Biobehav Rev       Date:  2012-08-13       Impact factor: 8.989

4.  Lipopolysaccharide-induced depressive-like behavior is associated with α₁-adrenoceptor dependent downregulation of the membrane GluR1 subunit in the mouse medial prefrontal cortex and ventral tegmental area.

Authors:  Miyu Sekio; Kenjiro Seki
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

5.  Dexmedetomidine Ameliorates Sleep Deprivation-Induced Depressive Behaviors in Mice.

Authors:  Eun-Jin Moon; Il-Gyu Ko; Sung-Eun Kim; Jun-Jang Jin; Lakkyong Hwang; Chang-Ju Kim; Hyeonjun An; Bong-Jae Lee; Jae-Woo Yi
Journal:  Int Neurourol J       Date:  2018-10-31       Impact factor: 2.835

Review 6.  Therapeutic Potential of Selectively Targeting the α2C-Adrenoceptor in Cognition, Depression, and Schizophrenia-New Developments and Future Perspective.

Authors:  Madeleine Monique Uys; Mohammed Shahid; Brian Herbert Harvey
Journal:  Front Psychiatry       Date:  2017-08-14       Impact factor: 4.157

7.  Successful Treatment of Refractory Cancer Pain and Depression with Continuous Intrathecal Administration of Dexmedetomidine and Morphine: A Case Report.

Authors:  Ge Huang; Guo Liu; Zhiguo Zhou; Jinfeng Yang; Chen Su
Journal:  Pain Ther       Date:  2020-07-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.